Bacterial topoisomerase inhibitors represent a promising class of antimicrobial agents that target essential enzymes involved in DNA replication and maintenance. By inhibiting enzymes such as DNA ...

Andrés Aguilera's laboratory, in collaboration with that of Ralf Wellinger (both professors in the Department of Genetics at the University of Seville in CABIMER) and with PharmaMAR, has identified ...

Childhood neuroblastoma is often a fatal disease. Despite initial treatment success, most patients relapse or develop resistance to the current therapies. A new approach using a combination of two ...

On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody and topoisomerase inhibitor conjugate. This approval marks a significant ...